Stock Events

Stock Events

Scholar Rock 

$43.90
41
-$0.28-0.63%Friday 20:00
-$0.40-0.91%Friday 23:43After hours

Statistics

Day High
43.92
Day Low
43.85
52W High
61.76
52W Low
27.07
Volume
29,746
Avg. Volume
-
Mkt Cap
5.35B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 10Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.98
-0.85
-0.73
-0.6
Expected EPS
-0.847177
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-377.94MNet Income

Analyst Ratings

$71.55Average Price Target
The highest estimate is ⁦84.00⁩.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
91%
Hold
9%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SRRK. It's not an investment recommendation.
Alphabet
9
GOOGL
NVIDIA
8
NVDA
Apple
7
AAPL
Tesla
7
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals works on treatments for cancer and inflammatory diseases, competing in the biologic space with Scholar Rock.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals focuses on serious diseases, including cystic fibrosis, a key area of interest for Scholar Rock.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical targets rare genetic diseases, overlapping with Scholar Rock's focus on niche, high-need patient populations.
Incyte
INCY
Mkt Cap24.54B
Incyte Corporation focuses on oncology and inflammation, competing in the same therapeutic areas as Scholar Rock.
Alnylam Pharmaceuticals
ALNY
Mkt Cap22.1B
Alnylam Pharmaceuticals works on RNAi therapeutics for genetically defined diseases, competing in the innovative treatment space with Scholar Rock.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is engaged in gene editing, a revolutionary approach that could compete with Scholar Rock's therapeutic strategies.

About

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Show More
CEO
David L. Hallal
Employees
289
Country
United States
ISIN
US80706P1030
WKN
000A2JMQW

Listings

MU
DE
2QK.MU
STU
DE
2QK.STU
F
DE
2QK.F
BOATS
BOATS
SRRK.BOATS

0 Comments

Share your thoughts

FAQs

What is Scholar Rock stock price today?▼
The current price of SRRK is $43.90 USD — it has decreased by -0.63% in the past 24 hours. Watch Scholar Rock stock price performance more closely on the chart.
What is Scholar Rock stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Scholar Rock stocks are traded under the ticker SRRK.
Is Scholar Rock stock price growing?▼
SRRK stock has risen by +5.25% compared to the previous week, the month change is a -6.22% fall, over the last year Scholar Rock has showed a +48.21% increase.
What is Scholar Rock market cap?▼
Today Scholar Rock has the market capitalization of 5.35B
When is the next Scholar Rock earnings date?▼
Scholar Rock is going to release the next earnings report on November 10, 2026.
What were Scholar Rock earnings last quarter?▼
SRRK earnings for the last quarter are -0.84 USD per share, whereas the estimation was -0.84 USD resulting in a +0.06% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Scholar Rock revenue for the last year?▼
Scholar Rock revenue for the last year amounts to 0 USD.
What is Scholar Rock net income for the last year?▼
SRRK net income for the last year is -377.94M USD.
How many employees does Scholar Rock have?▼
As of November 2, 2026, the company has 289 employees.
In which sector is Scholar Rock located?▼
Scholar Rock operates in the Health & Wellness sector.
When did Scholar Rock complete a stock split?▼
Scholar Rock has not had any recent stock splits.
Where is Scholar Rock headquartered?▼
Scholar Rock is headquartered in CAMBRIDGE, United States.